Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialGiant Biogene Holding Co. Ltd. ( (HK:2367) ) has issued an announcement. Giant Biogene Holding Co., Ltd. announced that its wholly owned subsidiary Shaanxi Giant Biotechnology has obtained a Medical Device Registration Certificate in China for a new product, the Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, indicated for intradermal injection to improve cheek smoothness. Billed as the world’s first recombinant collagen and sodium hyaluronate composite solution implant approved for this indication, the product expands the company’s collagen-based product portfolio, reinforces its R&D and industrial capabilities, and is expected to open wider market opportunities in skin rejuvenation as the company moves ahead with commercialization efforts to strengthen its leading position in the health and beauty sector. The most recent analyst rating on (HK:2367) stock is a Hold with a HK$39.50 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page. More about Giant Biogene Holding Co. Ltd. Giant Biogene Holding Co., Ltd. is a health and beauty-focused biotechnology company specializing in collagen-based medical and skincare solutions. Through subsidiaries such as Shaanxi Giant Biotechnology Co., Ltd., it develops and commercializes advanced recombinant collagen products aimed at skin rejuvenation and aesthetic treatments in the Chinese market. Average Trading Volume: 11,485,053 Technical Sentiment Signal: Sell Current Market Cap: HK$37.25B For an in-depth examination of 2367 stock, go to TipRanks’ Overview page.